Beneficial bioartificial livers

Science ◽  
2020 ◽  
Vol 369 (6500) ◽  
pp. 154.4-154
Author(s):  
Caitlin Czajka
Keyword(s):  
2021 ◽  
Vol 28 ◽  
Author(s):  
Xiaohong Li ◽  
Liang Wen ◽  
Jiao Liu ◽  
Xiaohong Wang

: End-stage liver diseases have long been a threat to human health, and so far, the treatment of these diseases lacks of effective means. Allogenic organ transplantation has become the last straw for most of the patients with end-stage liver diseases. However, this technique has been greatly limited by the serious shortage of donors and other factors, such as immune rejection, drug syndrome, and high cost. Recently, the emergence of three-dimensional (3D) bioprinting technologies, together with the magnetic resonance imaging (MRI) and computed tomography (CT) techniques, has driven the rapid growth of this field toward liver therapies. There are several basic requirements for liver 3D bioprinting. From information collection of diseased livers, to 3D printing of liver substitutes (containing the major structural, material and functional characters), and to clinical applications, suitable ‘bioinks’ and ‘bioprinters’ have played essential roles. In this review, we highlight the advanced ‘bioinks’ and ‘bioprinters’ that have been used for vascularized and innervated liver tissue 3D bioprinting. Further studies for the incorporation of biliary networks in the bioartificial livers have been emphasized. It is expected that when all the bottle-neck problems for liver 3D bioprinting are solved, batch (i.e. mass) and personalized production of bioartificial livers will make it very easy to treat end-stage liver diseases.


Author(s):  
Randall E. McClelland ◽  
Lola M. Reid
Keyword(s):  

2004 ◽  
Vol 26 (18) ◽  
pp. 1407-1412 ◽  
Author(s):  
Qin Meng ◽  
Guoliang Zhang ◽  
Danqing Wu

2008 ◽  
Vol 23 (5) ◽  
pp. 409-422 ◽  
Author(s):  
Wei Xu ◽  
Xiaohong Wang ◽  
Yongnian Yan ◽  
Renji Zhang

2020 ◽  
Vol 21 (17) ◽  
pp. 6215
Author(s):  
Cristina Olgasi ◽  
Alessia Cucci ◽  
Antonia Follenzi

Liver transplantation is the most common treatment for patients suffering from liver failure that is caused by congenital diseases, infectious agents, and environmental factors. Despite a high rate of patient survival following transplantation, organ availability remains the key limiting factor. As such, research has focused on the transplantation of different cell types that are capable of repopulating and restoring liver function. The best cellular mix capable of engrafting and proliferating over the long-term, as well as the optimal immunosuppression regimens, remain to be clearly well-defined. Hence, alternative strategies in the field of regenerative medicine have been explored. Since the discovery of induced pluripotent stem cells (iPSC) that have the potential of differentiating into a broad spectrum of cell types, many studies have reported the achievement of iPSCs differentiation into liver cells, such as hepatocytes, cholangiocytes, endothelial cells, and Kupffer cells. In parallel, an increasing interest in the study of self-assemble or matrix-guided three-dimensional (3D) organoids have paved the way for functional bioartificial livers. In this review, we will focus on the recent breakthroughs in the development of iPSCs-based liver organoids and the major drawbacks and challenges that need to be overcome for the development of future applications.


2003 ◽  
Vol 52 (3) ◽  
pp. 151-157 ◽  
Author(s):  
Naoya Kobayashi ◽  
Teru Okitsu ◽  
Noriaki Tanaka
Keyword(s):  

2012 ◽  
Vol 12 (7) ◽  
pp. 905-921 ◽  
Author(s):  
Geert AA Nibourg ◽  
Robert AFM Chamuleau ◽  
Thomas M van Gulik ◽  
Ruurdtje Hoekstra

Stem Cells ◽  
2016 ◽  
Vol 35 (1) ◽  
pp. 42-50 ◽  
Author(s):  
Clara T. Nicolas ◽  
Raymond D. Hickey ◽  
Harvey S. Chen ◽  
Shennen A. Mao ◽  
Manuela Lopera Higuita ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document